|
1
|
Anthrax lethal factor proteolysis and inactivation of MAPK kinase.
|
J Biol Chem
|
2003
|
2.32
|
|
2
|
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
|
Cancer Res
|
2008
|
1.76
|
|
3
|
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
|
Proc Natl Acad Sci U S A
|
2002
|
1.38
|
|
4
|
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
|
Microb Pathog
|
2007
|
1.36
|
|
5
|
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
|
Mol Cancer Ther
|
2005
|
1.27
|
|
6
|
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha.
|
J Biol Chem
|
2002
|
1.26
|
|
7
|
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
|
Clin Cancer Res
|
2006
|
1.08
|
|
8
|
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.
|
PLoS Pathog
|
2007
|
1.05
|
|
9
|
MEK genomics in development and disease.
|
Brief Funct Genomics
|
2012
|
1.04
|
|
10
|
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
|
Mol Cancer Ther
|
2008
|
1.00
|
|
11
|
Pathophysiology of anthrax.
|
Front Biosci (Landmark Ed)
|
2009
|
0.96
|
|
12
|
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
|
Cell Cycle
|
2008
|
0.96
|
|
13
|
Involvement of domain II in toxicity of anthrax lethal factor.
|
J Biol Chem
|
2004
|
0.94
|
|
14
|
Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous.
|
Invest Ophthalmol Vis Sci
|
2013
|
0.94
|
|
15
|
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
|
Mol Cancer Ther
|
2008
|
0.91
|
|
16
|
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.
|
Int J Oncol
|
2008
|
0.90
|
|
17
|
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
|
Mol Cancer Ther
|
2010
|
0.89
|
|
18
|
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
|
Clin Cancer Res
|
2007
|
0.88
|
|
19
|
Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C.
|
EMBO J
|
2003
|
0.87
|
|
20
|
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
|
Mol Cancer Res
|
2009
|
0.84
|
|
21
|
Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.
|
PLoS One
|
2009
|
0.84
|
|
22
|
Developmental biology: an arresting activity.
|
Nature
|
2002
|
0.84
|
|
23
|
MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.
|
PLoS One
|
2011
|
0.84
|
|
24
|
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
|
Invest Ophthalmol Vis Sci
|
2011
|
0.83
|
|
25
|
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
26
|
Novel protein targeted therapy of metastatic melanoma.
|
Curr Pharm Des
|
2003
|
0.83
|
|
27
|
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.
|
Clin Dev Immunol
|
2013
|
0.82
|
|
28
|
Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways.
|
Methods Enzymol
|
2008
|
0.82
|
|
29
|
Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes.
|
Dev Biol
|
2002
|
0.78
|
|
30
|
Xenopus tropicalis oocytes: more than just a beautiful genome.
|
Methods Mol Biol
|
2006
|
0.76
|
|
31
|
A tribute to George F. Vande Woude, a man of character: 2006 Scientific Symposium Winning the War against Cancer: from Genomics to Bedside and Back.
|
Cancer Res
|
2007
|
0.75
|